Goldman Sachs Upgrades Pluxee to Neutral as Brazil's PAT Reform Hit Gets Priced In

Why Goldman Sachs Stopped Calling Pluxee a Sell

Goldman Sachs Research has upgraded Pluxee, the employee benefits provider, to Neutral from Sell, sending the shares up more than 3% on Tuesday. The move comes a day after the upgrade and follows a bruising period for the stock, which had fallen 31% since Goldman added it to its sell list on October 14, 2024. That decline lagged the STOXX 600 and FTSE World Europe by 55 percentage points, a gap that Goldman attributed to Brazil regulation and weaker-than-expected revenue trends.

The latest trigger for the reset was Pluxee's guidance for fiscal 2027 EBITDA of at least €440 million, a decline of up to 10% from the prior year. Management tied the drop to equalizing merchant terms across all its meal and food programs in Brazil after the PAT reform. The guidance landed well below already lowered expectations, prompting Goldman to cut its earnings-per-share estimates by about 10% through its forecast period.

But the bank also found reasons to turn less bearish. It raised its 12-month price target to €12.20 from €11.60 and lifted its target earnings multiple to 8.5 times from 7.25 times. It also increased dividend-per-share estimates by about 45% on average for fiscal 2027-2030 after Pluxee lifted its dividend payout ratio to 40% from at least 25% previously. With the shares closing at €11.93 on November 6, the new target implies just 2.3% upside.

Inside the Brazil Reset and What It Means for Pluxee's Valuation

Why the Brazil PAT Reform Is the Real Story

Pluxee's fiscal 2027 guidance cut is not a generic earnings miss. It is the direct result of Brazil's PAT reform, which forced the company to equalize merchant terms across all its meal and food programs. Goldman estimates the annualization of changed commercial terms and their extension to more programs will create a year-on-year Brazil pricing impact of about €110 million, driving a double-digit decline in Latin American organic revenue. That single regulatory change explains most of the earnings reset.

What Goldman's Upgrade Actually Signals

Goldman's shift to Neutral is not a bullish call. It is a recognition that the sell case has largely played out. The stock now trades at about 8 times expected 2027 earnings, a significant de-rating over two years. Goldman's fiscal 2027 and 2028 EBITDA forecasts are broadly in line with consensus rather than pointing to further downside. The upgrade reflects that the bad news is now in the price, not that Pluxee's fundamentals have improved.

The Dividend Pivot and What It Tells Us

Pluxee's decision to raise its payout ratio to 40% from at least 25% is a notable capital allocation signal. Goldman responded by raising dividend-per-share estimates by about 45% on average for fiscal 2027-2030. For context, a higher payout ratio can indicate management confidence in cash generation, but it can also signal limited high-return reinvestment opportunities. In Pluxee's case, the move may be designed to support the share price while the Brazil transition plays out.

Where the Growth Is Coming From

Goldman expects flat organic operating revenue growth in Continental Europe and double-digit growth in the Rest of World segment. Group organic revenue growth is forecast at -3.7% for fiscal 2027, down from 0.7% in fiscal 2026. EBITDA is seen falling about 10% next year before growing about 6-8% over fiscal 2028-2031. The recovery hinges on Brazil stabilizing and France's meal voucher reforms becoming clearer.

What Remains Unresolved

Two key uncertainties persist. First, the full earnings impact of Brazil's PAT reform is still not clear, and further guidance resets cannot be ruled out. Second, France's meal voucher reforms could reshape Pluxee's largest market. Until both are resolved, the stock is likely to trade in a narrow range around Goldman's €12.20 target, with limited upside for investors willing to wait.

What Investors Should Watch Before Pluxee's Next Earnings

Goldman's upgrade is a signal that the worst of Pluxee's Brazil-driven earnings reset is priced in, not that the company is out of trouble.

For investors holding or considering Pluxee, the key issue is whether fiscal 2027 EBITDA lands at the bottom end of guidance or below it. Goldman forecasts €441 million, just 0.9% above Visible Alpha consensus and at the low end of company guidance. Any further deterioration in Brazil could force another reset.

• Watch the Brazil PAT reform impact: Goldman estimates a €110 million year-on-year pricing hit. Any update on whether this figure is final or could grow is the single most important near-term catalyst.
• Track France's meal voucher reforms: France is a core market, and clarity on regulatory changes there could either stabilize or further pressure Pluxee's Continental Europe outlook.
• Monitor the dividend: The 40% payout ratio supports the stock, but if earnings decline further, the dividend could come under pressure or limit reinvestment.
• Compare against consensus: Goldman's FY2027 and FY2028 EBITDA forecasts are broadly in line with consensus. If consensus starts to move lower, the Neutral rating could be revisited.

Key metrics to watch: Pluxee's next earnings date, any update on Brazil PAT reform implementation, and France's meal voucher reform timeline.